VectorY gains exclusive rights to evaluate and potentially license SHP-DB1, enhancing its neurodegenerative disease therapy pipeline. SHP-DB1, an engineered AAV5 capsid, offers improved brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback